ROHTO PHARMACEUTICAL CO.,LTD.
Medium- to Long-Term Growth Strategy 2026
Earlier from Rohto Pharmaceutical
- Rohto Pharmaceutical: バージャー病、膠原病により生じる難治性虚血性（非動脈硬化性）下肢潰瘍に対するRE-01細胞治療の第II相医師主導治験を開始
- Notice Regarding the Status of Repurchase of Shares and Completion of Repurchase
- Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
- Notice Regarding the Status of Repurchase of Shares